Nice Ltd Reports Q1 Earnings Miss, Shares Plunge 22.5%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2026
0mins
Source: Globenewswire
Nice Ltd's stock fell 22.5% after reporting disappointing Q1 2026 earnings, hitting a 52-week low.
The company reported adjusted earnings per share of $0.77, missing expectations by $1.75, despite total revenue of $768.6 million exceeding sales forecasts. The weak guidance for Q2 revenue, projected between $761 million and $771 million, also contributed to investor concerns, especially as the broader market, including the S&P 500 and Nasdaq, showed gains.
This significant earnings miss and lowered guidance have raised doubts about Nice's growth prospects, leading to a sharp decline in stock price, reflecting investor disappointment amid a generally positive market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NICE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NICE
Wall Street analysts forecast NICE stock price to rise
15 Analyst Rating
10 Buy
5 Hold
0 Sell
Moderate Buy
Current: 90.640
Low
120.00
Averages
158.57
High
200.00
Current: 90.640
Low
120.00
Averages
158.57
High
200.00
About NICE
NICE Ltd., formerly NICE-Systems Ltd., is a global enterprise software provider. The Company's segments include Customer Interactions Solutions and Financial Crime and Compliance Solutions. The Customer Interactions Solutions segment provides data-driven insights that enable businesses to deliver personalized experiences to customers. The Financial Crime and Compliance Solutions segment provides real-time and cross-channel fraud prevention, anti-money laundering, brokerage compliance, and enterprise-wide case management. The Company serves contact centers, back-office operations, and retail branches across various industries, including communications, banking, insurance, healthcare, business process outsourcing (BPO), government, utilities, travel, and entertainment. Its multi-channel recording and interaction management solutions enable organizations to capture structured and unstructured customer interaction and transaction data from multiple channels.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Is It Time to Reload Your Underinvested Portfolio?
- Shopify Stock Fluctuations: Shopify's stock has dropped 40% since last October, currently valued at $154 billion; despite pressures from slowing sales growth and rising interest rates, its Q1 revenue growth rate of 34% highlights its significance in the future of e-commerce.
- Nice's Customer Service Technology: Nice Ltd, with a market cap of $5.4 billion, derives only 14% of its cloud revenue from AI, yet its Q1 recurring revenue grew 66% year-over-year, showcasing its strong performance and growth potential in the customer service market.
- Viking Therapeutics' Drug Development: Viking Therapeutics is conducting phase 3 trials for its GLP-1 weight-loss drug VK2735, currently valued at $3.8 billion; analysts unanimously rate its stock as a strong buy with a target price of $95.40, reflecting confidence in its market potential.
- Investor Focus on Emerging Stocks: Despite overall market volatility, investor interest in Shopify, Nice, and Viking indicates optimism towards these growth stocks, particularly in the long-term growth prospects within the e-commerce and health sectors.
See More
Analysis of Shopify's Stock Price Decline
- Shopify's Stock Decline: Shopify's shares have fallen 40% since October, driven by slowing sales growth, rising interest rates, and potential threats from AI, although these concerns may be overstated.
- Nice Ltd's Customer Service Edge: Nice Ltd's platform facilitates over 20 billion interactions annually, and while AI accounts for only 14% of its cloud revenue, its annualized revenue has reached $345 million, indicating strong growth potential.
- Viking Therapeutics' Market Potential: Viking Therapeutics' VK2735 is in phase 3 trials and could disrupt the $200 billion obesity drug market, with analysts setting a target price of $95.40, representing a 200% upside from current levels.
- Cautious Investor Sentiment: Despite stocks remaining above late-March lows, many investors are on the sidelines due to concerns about a market pullback, particularly in the current economic climate, which challenges confidence in reinvesting.
See More
Concentrix Expands Partnership with NiCE to Enhance Agentic AI Solutions
- Partnership Upgrade: Concentrix has elevated its partnership with NiCE to Platinum status, reflecting the deep experience both teams have in delivering agentic AI in complex and regulated environments, aimed at enhancing enterprise customer service efficiency and value.
- AI Application Expansion: Together, they focus on deploying agentic AI in voice and chat systems to help enterprises resolve customer issues faster, thereby improving customer satisfaction and strengthening market competitiveness.
- Integration and Optimization: Concentrix accelerates the value realization of the NiCE Cognigy platform through its deep integration expertise and operational scale, ensuring effective AI operation in real environments and driving digital transformation for enterprises.
- Industry Impact: Guided by Concentrix's Agentic Operating Framework and extensive deployment experience, the company optimizes AI performance in complex environments, helping over 2,000 complex organizations worldwide achieve measurable business outcomes.
See More
Tech Stocks Poised for Future Growth
- Rubrik's Market Leadership: Rubrik has been named a leader in the backup and data protection space by Gartner for six consecutive years, with 2022 revenue reaching $1.26 billion, a 53% year-over-year increase, and is expected to achieve a small profit this year, showcasing its strong competitiveness in the rapidly growing cybersecurity market.
- Nice's AI Customer Service Innovation: Nice leverages AI to automate customer service, handling over 20 billion customer interactions annually, with 2022 revenue nearing $3 billion and projected earnings per share between $10.85 and $11.05 this year, indicating its leadership position and future growth potential in the CCaaS industry.
- Nebius's Cloud Computing Outlook: Nebius specializes in AI infrastructure and, despite currently being unprofitable, has distinguished itself through major partnerships with Microsoft and Meta, with analysts projecting over 500% revenue growth this year to $3.3 billion, highlighting its significant potential in the AI infrastructure market.
- Industry Growth Trends: According to Precedence Research, the global cybersecurity market is expected to grow at an average annual rate of nearly 13% through 2034, while the AI infrastructure market is projected to grow at an annualized pace of 23%, providing vast market opportunities for companies like Rubrik, Nice, and Nebius.
See More
Nice Reports Significant Q1 Earnings Miss, Shares Plunge
- Significant Earnings Miss: Nice reported adjusted earnings per share of $0.77 on sales of $768.6 million for Q1, which, while exceeding Wall Street's sales expectations by approximately $7.7 million, fell short of earnings targets by $1.75, resulting in a 22.5% drop in share price despite a bullish market backdrop.
- Market Reaction: In a session where the S&P 500 rose by 1.4% and the Nasdaq Composite increased by 2%, Nice's stock plummeted due to disappointing demand from AI projects, leading to a year-to-date decline of about 14%.
- Weak Forward Guidance: The company guided for adjusted revenue between $761 million and $771 million for the current quarter, falling short of the previous analyst estimate of approximately $777.4 million, indicating a slowdown with an expected year-over-year growth of about 5.5%.
- Slightly Positive Full-Year Outlook: Although the full-year sales forecast of $3.17 billion to $3.19 billion slightly exceeds Wall Street expectations, investor disappointment over the soft Q2 guidance may impact future investment decisions.
See More
Nice's Q1 Profit Falls Short of Expectations, Stock Plummets
- Q1 Performance Miss: Nice reported non-GAAP earnings per share of $0.77 on sales of $768.6 million in Q1, which, while exceeding sales expectations by $7.7 million, fell short of earnings expectations by $1.75, leading to significant investor disappointment and stock price decline.
- Stock Price Plunge: Despite a bullish market backdrop with the S&P 500 up 1.4% and the Nasdaq Composite up 2%, Nice's stock plummeted 22.5% in Wednesday's trading, reflecting market concerns over its future growth prospects.
- Weak Guidance: The company’s guidance for Q2 adjusted revenue between $761 million and $771 million falls short of the analyst estimate of approximately $777.4 million, indicating a potential slowdown in demand for AI projects, which could adversely affect future performance.
- Slightly Positive Annual Outlook: Although the Q2 guidance is disappointing, Nice projects full-year sales between $3.17 billion and $3.19 billion, with adjusted earnings per share expected between $10.98 and $11.18, slightly exceeding Wall Street expectations, yet investors remain concerned about the short-term outlook.
See More
Is It Time to Reload Your Underinvested Portfolio?
- Shopify Stock Fluctuations: Shopify's stock has dropped 40% since last October, currently valued at $154 billion; despite pressures from slowing sales growth and rising interest rates, its Q1 revenue growth rate of 34% highlights its significance in the future of e-commerce.
- Nice's Customer Service Technology: Nice Ltd, with a market cap of $5.4 billion, derives only 14% of its cloud revenue from AI, yet its Q1 recurring revenue grew 66% year-over-year, showcasing its strong performance and growth potential in the customer service market.
- Viking Therapeutics' Drug Development: Viking Therapeutics is conducting phase 3 trials for its GLP-1 weight-loss drug VK2735, currently valued at $3.8 billion; analysts unanimously rate its stock as a strong buy with a target price of $95.40, reflecting confidence in its market potential.
- Investor Focus on Emerging Stocks: Despite overall market volatility, investor interest in Shopify, Nice, and Viking indicates optimism towards these growth stocks, particularly in the long-term growth prospects within the e-commerce and health sectors.
See More
Analysis of Shopify's Stock Price Decline
- Shopify's Stock Decline: Shopify's shares have fallen 40% since October, driven by slowing sales growth, rising interest rates, and potential threats from AI, although these concerns may be overstated.
- Nice Ltd's Customer Service Edge: Nice Ltd's platform facilitates over 20 billion interactions annually, and while AI accounts for only 14% of its cloud revenue, its annualized revenue has reached $345 million, indicating strong growth potential.
- Viking Therapeutics' Market Potential: Viking Therapeutics' VK2735 is in phase 3 trials and could disrupt the $200 billion obesity drug market, with analysts setting a target price of $95.40, representing a 200% upside from current levels.
- Cautious Investor Sentiment: Despite stocks remaining above late-March lows, many investors are on the sidelines due to concerns about a market pullback, particularly in the current economic climate, which challenges confidence in reinvesting.
See More
Concentrix Expands Partnership with NiCE to Enhance Agentic AI Solutions
- Partnership Upgrade: Concentrix has elevated its partnership with NiCE to Platinum status, reflecting the deep experience both teams have in delivering agentic AI in complex and regulated environments, aimed at enhancing enterprise customer service efficiency and value.
- AI Application Expansion: Together, they focus on deploying agentic AI in voice and chat systems to help enterprises resolve customer issues faster, thereby improving customer satisfaction and strengthening market competitiveness.
- Integration and Optimization: Concentrix accelerates the value realization of the NiCE Cognigy platform through its deep integration expertise and operational scale, ensuring effective AI operation in real environments and driving digital transformation for enterprises.
- Industry Impact: Guided by Concentrix's Agentic Operating Framework and extensive deployment experience, the company optimizes AI performance in complex environments, helping over 2,000 complex organizations worldwide achieve measurable business outcomes.
See More
Tech Stocks Poised for Future Growth
- Rubrik's Market Leadership: Rubrik has been named a leader in the backup and data protection space by Gartner for six consecutive years, with 2022 revenue reaching $1.26 billion, a 53% year-over-year increase, and is expected to achieve a small profit this year, showcasing its strong competitiveness in the rapidly growing cybersecurity market.
- Nice's AI Customer Service Innovation: Nice leverages AI to automate customer service, handling over 20 billion customer interactions annually, with 2022 revenue nearing $3 billion and projected earnings per share between $10.85 and $11.05 this year, indicating its leadership position and future growth potential in the CCaaS industry.
- Nebius's Cloud Computing Outlook: Nebius specializes in AI infrastructure and, despite currently being unprofitable, has distinguished itself through major partnerships with Microsoft and Meta, with analysts projecting over 500% revenue growth this year to $3.3 billion, highlighting its significant potential in the AI infrastructure market.
- Industry Growth Trends: According to Precedence Research, the global cybersecurity market is expected to grow at an average annual rate of nearly 13% through 2034, while the AI infrastructure market is projected to grow at an annualized pace of 23%, providing vast market opportunities for companies like Rubrik, Nice, and Nebius.
See More
Nice Reports Significant Q1 Earnings Miss, Shares Plunge
- Significant Earnings Miss: Nice reported adjusted earnings per share of $0.77 on sales of $768.6 million for Q1, which, while exceeding Wall Street's sales expectations by approximately $7.7 million, fell short of earnings targets by $1.75, resulting in a 22.5% drop in share price despite a bullish market backdrop.
- Market Reaction: In a session where the S&P 500 rose by 1.4% and the Nasdaq Composite increased by 2%, Nice's stock plummeted due to disappointing demand from AI projects, leading to a year-to-date decline of about 14%.
- Weak Forward Guidance: The company guided for adjusted revenue between $761 million and $771 million for the current quarter, falling short of the previous analyst estimate of approximately $777.4 million, indicating a slowdown with an expected year-over-year growth of about 5.5%.
- Slightly Positive Full-Year Outlook: Although the full-year sales forecast of $3.17 billion to $3.19 billion slightly exceeds Wall Street expectations, investor disappointment over the soft Q2 guidance may impact future investment decisions.
See More
Nice's Q1 Profit Falls Short of Expectations, Stock Plummets
- Q1 Performance Miss: Nice reported non-GAAP earnings per share of $0.77 on sales of $768.6 million in Q1, which, while exceeding sales expectations by $7.7 million, fell short of earnings expectations by $1.75, leading to significant investor disappointment and stock price decline.
- Stock Price Plunge: Despite a bullish market backdrop with the S&P 500 up 1.4% and the Nasdaq Composite up 2%, Nice's stock plummeted 22.5% in Wednesday's trading, reflecting market concerns over its future growth prospects.
- Weak Guidance: The company’s guidance for Q2 adjusted revenue between $761 million and $771 million falls short of the analyst estimate of approximately $777.4 million, indicating a potential slowdown in demand for AI projects, which could adversely affect future performance.
- Slightly Positive Annual Outlook: Although the Q2 guidance is disappointing, Nice projects full-year sales between $3.17 billion and $3.19 billion, with adjusted earnings per share expected between $10.98 and $11.18, slightly exceeding Wall Street expectations, yet investors remain concerned about the short-term outlook.
See More
